PTC-209 HBr

Research use only, not for human use.

PTC-209 HBr is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).

PTC-209 Hydrobromide is a novel potent BMI1-inhibitor, modulating the RE1.

PTC-209 (0.01-10 μM; 24-72 hours) induces a concentration- and time-dependent decrease in the cellular viability of all cell lines tested.PTC-209 (1-2.5 μM) inhibits STAT3 phosphorylation in A549 lung cancer cells and MDA-MB-231 breast cancer cells. Cell Viability Assay Cell Line:Lung (LNM35, A549 cells), breast (MDA-MB-231 and T47D cells), and colon (HT-29, HCT-116, and HCT8/S11 cells) Concentration:0.01-10 μM Incubation Time:24, 48, and 72 hour Result:Induced a concentration- and time-dependent decrease in the cellular viability of all cell lines tested.

PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume. Animal Model:Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)Dosage:60 mg/kg body weight Administration:Subcutaneously; once a day for 11 days Result:Significantly reduced tumor volume.

PTC-209 | PTC 209 | PTC209 Hydrobromide

Membrane Transporter/Ion Channel

NADPH

BMI-1

Cancer

——

1217022-63-3

576.1

C17H13Br2N5OS·HBr

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (173.58 mM)

Br.COC1=CC(Br)=C(NC2=NC(=CS2)C2=C(C)N=C3N=CC=CN23)C(Br)=C1

N-(2,6-Dibromo-4-methoxyphenyl)-4-(2-methylimidazo[1,2-a]pyrimidin-3-yl)-2-thiazolamine hydrobromide

(-20℃)

With Ice Pack

≥ 2 years